In contrast, SCLC exhibits marked plasticity driven by oncogenic factors such as MYC and frequent alterations in epigenetic regulators including CREBBP, EP300, and KMT2 family genes, which have been shown to influence lineage state transitions and therapeutic resistance [82,83]. This evidence concerns the gene EP300 and small cell lung carcinoma.